GlaxoSmithKline/£GSK
07:00
09:10
11:15
13:25
15:30
1D1W1MYTD1Y5YMAX
About GlaxoSmithKline
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Ticker
£GSK
Sector
Primary listing
LSE
Industry
Pharmaceuticals
Headquarters
Employees
68,629
ISIN
GB00BN7SWP63
Website
GlaxoSmithKline Metrics
BasicAdvanced
£57B
18.44
£0.76
0.27
£0.61
4.35%
Price and volume
Market cap
£57B
Beta
0.27
52-week high
£16.69
52-week low
£12.43
Average daily volume
9.4M
Dividend rate
£0.61
Financial strength
Current ratio
0.868
Quick ratio
0.575
Long term debt to equity
120.653
Total debt to equity
134.993
Dividend payout ratio (TTM)
78.91%
Interest coverage (TTM)
10.32%
Profitability
EBITDA (TTM)
8,654
Gross margin (TTM)
71.92%
Net profit margin (TTM)
10.00%
Operating margin (TTM)
19.83%
Effective tax rate (TTM)
13.90%
Revenue per employee (TTM)
£460,000
Management effectiveness
Return on assets (TTM)
6.55%
Return on equity (TTM)
27.10%
Valuation
Price to earnings (TTM)
18.438
Price to revenue (TTM)
1.817
Price to book
4.05
Price to tangible book (TTM)
-6.36
Price to free cash flow (TTM)
14.131
Free cash flow yield (TTM)
7.08%
Free cash flow per share (TTM)
99.32%
Dividend yield (TTM)
4.35%
Growth
Revenue change (TTM)
2.57%
Earnings per share change (TTM)
-30.07%
3-year revenue growth (CAGR)
5.66%
10-year revenue growth (CAGR)
3.20%
3-year earnings per share growth (CAGR)
-15.47%
10-year earnings per share growth (CAGR)
-11.61%
3-year dividend per share growth (CAGR)
-12.88%
10-year dividend per share growth (CAGR)
-4.67%
What the Analysts think about GlaxoSmithKline
Analyst ratings (Buy, Hold, Sell) for GlaxoSmithKline stock.
Bulls say / Bears say
GSK's experimental drug depemokimab has shown promise in reducing severe asthma attacks, with potential peak annual sales of £3 billion, indicating a strong pipeline for future growth. (reuters.com)
The company raised its 2023 earnings outlook, expecting adjusted earnings per share growth of 14%-17%, driven by strong vaccine and HIV drug sales. (aol.com)
GSK's acquisition of Aiolos Bio for over $1 billion enhances its asthma treatment portfolio, positioning the company for increased market share in respiratory therapies. (wikipedia.org)
Sales of GSK's RSV vaccine Arexvy have declined in the U.S. due to narrowed age group recommendations and reclassification as a one-time shot, impacting revenue projections. (reuters.com)
JPMorgan lowered its price target for GSK shares to £15.50, citing concerns over declining vaccine sales and potential earnings erosion in the HIV segment. (investing.com)
GSK's shares have underperformed since the Haleon spinoff in 2022, with key drug patents set to expire and falling vaccine sales, making the company vulnerable to activist investor campaigns. (bloomberg.com)
Data summarised monthly by Lightyear AI. Last updated on 29 Jun 2025.
GlaxoSmithKline Financial Performance
Revenues and expenses
GlaxoSmithKline Earnings Performance
Company profitability
GlaxoSmithKline News
AllArticlesVideos
Britain's GSK Asserts It Is 'Well Positioned' To Mitigate Potential Tariffs After Strong Q1 Cancer And HIV Drug Sales
Benzinga·2 months ago
Cervarix Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts | GSK Leads Cervarix Market Amid Global Vaccination Efforts
GlobeNewsWire·2 months ago
GSK Posts Strong Results, Says 'Well Positioned' in Case of Pharma Tariffs
Investopedia·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for GlaxoSmithKline stock?
GlaxoSmithKline (GSK) has a market cap of £57B as of June 30, 2025.
What is the P/E ratio for GlaxoSmithKline stock?
The price to earnings (P/E) ratio for GlaxoSmithKline (GSK) stock is 18.44 as of June 30, 2025.
Does GlaxoSmithKline stock pay dividends?
Yes, the GlaxoSmithKline (GSK) stock pays dividends to shareholders. As of June 30, 2025, the dividend rate is £0.61 and the yield is 4.35%. GlaxoSmithKline has a payout ratio of 78.91% on a trailing twelve-month basis.
When is the next GlaxoSmithKline dividend payment date?
The next GlaxoSmithKline (GSK) dividend payment date is unconfirmed.
What is the beta indicator for GlaxoSmithKline?
GlaxoSmithKline (GSK) has a beta rating of 0.27. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.